Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.

MLA

Jabbour, Serge, et al. “Switching to Tirzepatide 5 Mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.” Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, vol. 30, no. 8, Aug. 2024, pp. 701–09. EBSCOhost, https://doi.org/10.1016/j.eprac.2024.05.005.

APA

Jabbour, S., Paik, J. S., Aleppo, G., Sharma, P., Gomez Valderas, E., & Benneyworth, B. D. (2024). Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 30(8), 701–709. https://doi.org/10.1016/j.eprac.2024.05.005

Chicago

Jabbour, Serge, Jim S Paik, Grazia Aleppo, Palash Sharma, Elisa Gomez Valderas, and Brian D Benneyworth. 2024. “Switching to Tirzepatide 5 Mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.” Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 30 (8): 701–9. doi:10.1016/j.eprac.2024.05.005.